(Sharecast News) - Pharmacitucal firm Shield Therapeutics said on Tuesday that it had inked an exclusive licence agreement for its ACCRUFeR iron deficiency asset in Japan with VITAL-NET.
Shield Therapeutics said VITAL-NET will undertake and be responsible for all costs, including clinical and regulatory, related to activities required to achieve marketing...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE